Welcome to our dedicated page for Ikena Oncology SEC filings (Ticker: IKNA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Ikena Oncology's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Ikena Oncology's regulatory disclosures and financial reporting.
Schedule 13D/A (Am. No. 5) — ImageneBio, Inc.
OrbiMed Advisors LLC and affiliated funds updated their stake following the 25 Jul 2025 1-for-12 reverse split and PIPE financing tied to the Ikena-Inmagene merger. Outstanding shares rose to 11,181,676, cutting the group’s ownership by >1 ppt to 773,754 shares (6.92%).
Break-down: OrbiMed Private Investments VI, LP holds 753,063 shares (6.73%); Worldwide Healthcare Trust PLC, advised by OrbiMed Capital LLC, owns 135,516 shares (1.21%); OrbiMed Genesis Master Fund, LP holds 20,691 shares (0.19%). Voting/dispositive power is largely shared among OrbiMed Advisors, OrbiMed Capital GP VI LLC, and OrbiMed Genesis GP LLC.
On 25 Jul 2025 OPI VI bought 83,611 PIPE shares at $2.49 each (≈$29.90 post-split); cash came from partnership working capital. The investors secured demand, piggy-back and Form S-3 registration rights; Director David P. Bonita’s equity awards are assigned to OrbiMed. The group states no present plans for further corporate actions but may trade shares opportunistically.